102 related articles for article (PubMed ID: 14726506)
1. Temozolomide for melanoma: new toxicities and new opportunities.
Gajewski TF
J Clin Oncol; 2004 Feb; 22(4):580-1. PubMed ID: 14726506
[No Abstract] [Full Text] [Related]
2. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Su YB; Sohn S; Krown SE; Livingston PO; Wolchok JD; Quinn C; Williams L; Foster T; Sepkowitz KA; Chapman PB
J Clin Oncol; 2004 Feb; 22(4):610-6. PubMed ID: 14726505
[TBL] [Abstract][Full Text] [Related]
3. How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience.
Wick W; Weller M
J Clin Oncol; 2005 Jun; 23(18):4235-6; author reply 4236. PubMed ID: 15961774
[No Abstract] [Full Text] [Related]
4. Is protracted low-dose temozolomide feasible in glioma patients?
Tosoni A; Cavallo G; Ermani M; Scopece L; Franceschi E; Ghimenton C; Gardiman M; Pasetto L; Blatt V; Brandes AA
Neurology; 2006 Feb; 66(3):427-9. PubMed ID: 16476947
[TBL] [Abstract][Full Text] [Related]
5. Is protracted low-dose temozolomide feasible in glioma patients?
Wong ET
Neurology; 2006 Aug; 67(3):543-4; author reply 543-4. PubMed ID: 16894133
[No Abstract] [Full Text] [Related]
6. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Neyns B; Tosoni A; Hwu WJ; Reardon DA
Cancer; 2010 Jun; 116(12):2868-77. PubMed ID: 20564393
[TBL] [Abstract][Full Text] [Related]
7. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide.
Schwarzberg AB; Stover EH; Sengupta T; Michelini A; Vincitore M; Baden LR; Kulke MH
Cancer Invest; 2007 Jun; 25(4):249-55. PubMed ID: 17612935
[TBL] [Abstract][Full Text] [Related]
8. [Phototoxicity of dacarbazine (Deticene) not reinduced by temozolomide (Temodal)].
Schmutz JL; Barbaud A; Trechot P
Ann Dermatol Venereol; 2006 May; 133(5 Pt 1):500. PubMed ID: 16760848
[No Abstract] [Full Text] [Related]
9. Pneumocystis jirovecii pneumonia complicating the progress of a patient with glioblastoma multiforme receiving temozolomide.
Gorospe Sarasúa L; Ureña-Vacas A; Muñoz Del Toro JR
Arch Bronconeumol; 2016 Oct; 52(10):534-5. PubMed ID: 27021139
[No Abstract] [Full Text] [Related]
10. Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients.
Teimouri F; Nikfar S; Abdollahi M
Melanoma Res; 2013 Oct; 23(5):381-9. PubMed ID: 23880781
[TBL] [Abstract][Full Text] [Related]
11. Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma.
Rasi G; Terzoli E; Izzo F; Pierimarchi P; Ranuzzi M; Sinibaldi-Vallebona P; Tuthill C; Garaci E
Melanoma Res; 2000 Apr; 10(2):189-92. PubMed ID: 10803720
[No Abstract] [Full Text] [Related]
12. Temozolomide-related infections: review of the literature.
Kizilarslanoglu MC; Aksoy S; Yildirim NO; Ararat E; Sahin I; Altundag K
J BUON; 2011; 16(3):547-50. PubMed ID: 22006764
[TBL] [Abstract][Full Text] [Related]
13. The safety of temozolomide in the treatment of malignancies.
Trinh VA; Patel SP; Hwu WJ
Expert Opin Drug Saf; 2009 Jul; 8(4):493-9. PubMed ID: 19435405
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of extended-dose temozolomide in patients with melanoma.
Rietschel P; Wolchok JD; Krown S; Gerst S; Jungbluth AA; Busam K; Smith K; Orlow I; Panageas K; Chapman PB
J Clin Oncol; 2008 May; 26(14):2299-304. PubMed ID: 18467721
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
16. Dacarbazine but not temozolomide induces phototoxic dermatitis in patients with malignant melanoma.
Treudler R; Georgieva J; Geilen CC; Orfanos CE
J Am Acad Dermatol; 2004 May; 50(5):783-5. PubMed ID: 15097966
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
[TBL] [Abstract][Full Text] [Related]
18. Management of temozolomide toxicity by nurse practitioners in neuro-oncology.
Zwinkels H; Roon K; Jeurissen FJ; Taphoorn MJ; Hop WC; Vecht CJ
Oncol Nurs Forum; 2009 Mar; 36(2):225-31. PubMed ID: 19273412
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide: a novel oral alkylating agent.
Danson SJ; Middleton MR
Expert Rev Anticancer Ther; 2001 Jun; 1(1):13-9. PubMed ID: 12113120
[TBL] [Abstract][Full Text] [Related]
20. Comment on "Opportunistic cytomegalovirus infection in a patient receiving temozolomide for treatment of malignant glioma".
Gousias K; Kyritsis A
J Clin Neurosci; 2010 Mar; 17(3):412. PubMed ID: 20079651
[No Abstract] [Full Text] [Related]
[Next] [New Search]
